Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: A subgroup analysis of the ENGAGE AF-TIMI 48 trial

European Heart Journal

Volumn 36, Issue 33, 2015, Pages 2239-2245

  Steffel, J ^a   Giugliano, R P ^b   Braunwald, E ^b   Murphy, S A ^b   Atar, D ^c   Heidbuchel, H ^d   Camm, A J ^e   Antman, E M ^b   Ruff, C T ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d HASSELT UNIVERSITY   (Belgium)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Amiodarone; Anticoagulation; Atrial fibrillation; Edoxaban

Indexed keywords

AMIODARONE; DRONEDARONE; EDOXABAN; QUINIDINE; VERAPAMIL; WARFARIN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; EXPLORATORY RESEARCH; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; CLINICAL TRIAL; COMPARATIVE STUDY; HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; STROKE; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; STROKE; THIAZOLES; TREATMENT OUTCOME; WARFARIN;

EID: 84941273179     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv201     Document Type: Article

References (16)

1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, RuzylloW, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, the EAFTI. Edoxaban versus warfarin in patients with atrial fibrillation.NEngl J Med 2013;369:2093-2104.
2. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the effective anticoagulation with factor xa next generation in atrial fibrillation-Thrombolysis in myocardial infarction study 48 (engage af-Timi 48). Am Heart J 2010;160:635-641.
3. Wessler JD, Grip LT, Mendell J, Giugliano RP. The p-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495-2502.
4. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M. Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor. Am J Cardiovasc Drugs 2013;13:331-342.
5. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012;107:925-936.
6. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, Cobbe SM, Widdershoven JW, Baur LH, Levy S, Crijns HJ. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the euro heart survey on atrial fibrillation. Eur Heart J 2008;29:1181-1189.
7. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: An analysis of data from the randomised, double-blind engage AF-TIMI 48 trial. Lancet Mar 10 [Epub ahead of print]. 2015; pii: S0140-6736: 61943-61947.
8. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3: 692-694.
9. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J 2011;32:1968-1976.
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
13. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the re-ly trial. J Thromb Haemost 2011;9:2168-2175.
14. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15(Suppl 1):9S-16S.
15. Steffel J, Ruff CT, Goldhaber S, Brunckhorst C. Stroke prevention in atrial fibrillation. Bremen: UniMed; 2014.
16. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-1450.